Johnson & Johnson makes $465 million equity investment in Sail Biomedicines - JNJ News | RalliesJohnson & Johnson makes $465 million equity investment in Sail Biomedicines
J
JNJ• Johnson & Johnson invests in Sail Biomedicines and secures option to acquire it
- Johnson & Johnson agreed to invest $465 million in Sail Biomedicines through an equity investment.
- Total initial payments are set at $785 million, tied to a collaboration on in vivo CAR-T programs for immune-mediated diseases.
- The deal includes up to $140 million in contingent payments if development milestones are met.
- Johnson & Johnson also secured an exclusive option to acquire Sail for $2.58 billion.
•
